Annual General Meeting 2016 in Karo Pharma AB (publ)

STOCKHOLM, Sweden, May 12, 2016 – At today’s Annual General Meeting in Karo Pharma the following main resolutions were passed.

The AGM voted in favour of adopting the income statements and balance sheets for the Group and the parent company, and decided that fund at the disposal of the general meeting, amounting to SEK 359,757,654, including the loss for the year amounting to SEK – 61,685,826, should be carried forward. Thus, it was resolved that no dividend should be paid for the financial year 2015.

The AGM further discharged the Board members and the CEO from liability, re-elected the ordinary board members Anders Lönner, Thomas Hedner, Per-Anders Johansson and Jean Lycke. Anders Lönner was elected Chairman of the Board.

The AGM resolved that the Board shall consist of four ordinary members and no deputy members.

The AGM further resolved in accordance with the Board’s proposal on amendment of the articles of association.

The AGM resolved that the Board’s fees shall remain unchanged at SEK 420,000 for the Chairman of the Board and SEK 150,000 for each of the other members of the Board.

The accounting firm PricewaterhouseCoopers AB was re-elected as the company’s auditor until the AGM 2017.

The AGM resolved in accordance with the proposal of the nomination committee on principles for the nomination committee.

The AGM also resolved in accordance with the Board’s proposal on guidelines for remuneration of executive management.

Lastly, the Board was authorized to, on one or several occasions prior to the next annual general, resolve on new share issues. The number of shares to be issued by virtue of the authorization shall not exceed 10 per cent of the registered share capital (at the time of the share issue resolution). The new share may be made with our without deviation from the shareholders’ pre-emption right and with or without terms of issue in kind or set-off or other terms.

For further information, please contact:
Henrik Palm, CFO, mobile phone +46 70 540 40 14 or e-mail henrik.palm@karopharma.se

About Karo Pharma
Karo Pharma is a health care company focused on developing and marketing of products to pharmacies, fast-moving consumer goods and the fealth care directly. Karo Pharma is listed on Nasdaq Stockholm.

Karo Pharma publishes this information in accordance with the Swedish Securities Markets Act. The information was submitted for publication on May 12, 2016, at 9:00 pm CET.

This press release is also available at www.karopharma.com and www.newsroom.cision.com

About Us

Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.

Subscribe

Documents & Links